Journal article

Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes

CY Cheah, D Chihara, JE Romaguera, NH Fowler, JF Seymour, FB Hagemeister, RE Champlin, ML Wang

Annals of Oncology | OXFORD UNIV PRESS | Published : 2015

DOI: 10.1093/annonc/mdv111

Citation metrics

60Web of Science
68Scopus

Keywords

Oncology
Kaplan-Meier Estimate
Biomarkers, Tumor
Humans
Middle Aged
Life Sciences & Biomedicine
Progression-Free Survival
Protein-Tyrosine Kinases
Lymphoma, Mantle-Cell
Molecular Targeted Therapy
Bruton'S Tyrosine Kinase Inhibitors
Aged, 80 and Over
Male
Treatment Failure
Ibrutinib
Prognosis
L-Lactate Dehydrogenase
Risk Factors
Drug Substitution
Pyrimidines
Retrospective Studies
Adult
Female
Protein Kinase Inhibitors
Salvage Therapy
Pyrazoles
Texas
Drug Resistance, Neoplasm
Science & Technology
Proportional Hazards Models
Agammaglobulinaemia Tyrosine Kinase
Treatment
Time Factors
Antineoplastic Agents
Disease Progression
Mantle Cell Lymphoma
Aged